Analytik Jena Closed Third Quarter Below Expectations
Analytik Jena AG closed the third quarter 2013/2014 below expectations. After nine months in the financial year 2013/2014, the Thuringian manufacturer of analytical measuring technology, life science instruments and optoelectronics generated consolidated revenue of EUR 89.7 m (previous year: EUR 71.3 m). Although this was 25.8 % more than in the comparable period of the previous year, the revenue increases resulted primarily from the project business of subsidiary AJZ Engineering, which was again fully consolidated and whose remaining shares (51.0 %) Analytik Jena AG reacquired on October 2, 2013 and in which it now again holds 100.0 %.
In its core instrument business, Analytik Jena Group generated revenue of EUR 74.6 m after nine months of the financial year, corresponding to 4.7 % more than in the previous year (previous year: EUR 71.3 m). Consolidated within this is the revenue of the UVP Group, which had not yet been included in the first six months of the previous year. Both the largest business unit Analytical Instrumentation and the Consumer Optics business with the DOCTER® brand, which is included in the Optics business unit, recorded revenue declines after nine months.
On the Group level Analytik Jena AG achieved earnings before interest, taxes, depreciation, and amortization (EBITDA) of EUR 4.3 m (previous year: EUR 5.6 m). Earnings before interest and taxes (EBIT) amounted to EUR 0.6 m (previous year: EUR 2.3 m). The operating result was negatively affected particularly by lower organic revenue in all three business units and respective losses after nine months in Life Science and Optics. All in all, the Group recorded a consolidated net loss in the first nine months of the financial year of EUR 3.3 m (previous year consolidated net loss: EUR 0.6 m).
Analytik Jena AG expects revenue in the instrument business of more than EUR 100.0 m for the current financial year 2013/2014. Not taken into account in this forecast is the revenue expected from the project business. Despite the unsatisfactory earnings development after nine months, Analytik Jena continues to expect an operating profit (EBIT) of around EUR 3.0 m based on the forecast and order entries in the fourth quarter.
Most read news
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.